特刊“关于针对关注和感兴趣的 SARS-CoV-2 变体的当前和未来疫苗的新见解”
Special Issue "New Insights into Current and Future Vaccines against SARS-CoV-2 Variants of Concern and Interest".
作者信息
Qu Bingqian, Li Xue
机构信息
Division of Veterinary Medicine, Paul Ehrlich Institute, 63225 Langen, Germany.
European Virus Bioinformatics Center, 07743 Jena, Germany.
出版信息
Vaccines (Basel). 2023 Mar 6;11(3):603. doi: 10.3390/vaccines11030603.
Abstract
The coronavirus (COVID-19) pandemic has been a global threat for the past three years at the time of writing, leading to more than 675 million confirmed cases and 6 [...].
摘要
在撰写本文时，过去三年里冠状病毒（COVID-19）大流行一直是全球威胁，导致超过6.75亿确诊病例以及6 [...].
相似文献
1
Special Issue "New Insights into Current and Future Vaccines against SARS-CoV-2 Variants of Concern and Interest".特刊“关于针对关注和感兴趣的 SARS-CoV-2 变体的当前和未来疫苗的新见解”
Vaccines (Basel). 2023 Mar 6;11(3):603. doi: 10.3390/vaccines11030603.
2
Advances in Next-Generation Coronavirus Vaccines in Response to Future Virus Evolution.应对未来病毒进化的新一代冠状病毒疫苗进展
Vaccines (Basel). 2022 Nov 29;10(12):2035. doi: 10.3390/vaccines10122035.
3
Developing pan-β-coronavirus vaccines against emerging SARS-CoV-2 variants of concern.开发针对新出现的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变异株的泛β冠状病毒疫苗。
Trends Immunol. 2022 Mar;43(3):170-172. doi: 10.1016/j.it.2022.01.009. Epub 2022 Jan 14.
4
5
Iota-Carrageenan Inhibits Replication of SARS-CoV-2 and the Respective Variants of Concern Alpha, Beta, Gamma and Delta.iota-卡拉胶抑制 SARS-CoV-2 及其关注的 Alpha、Beta、Gamma 和 Delta 变体的复制。
Int J Mol Sci. 2021 Dec 8;22(24):13202. doi: 10.3390/ijms222413202.
6
COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants.2019冠状病毒病疫苗：它们对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）及其新出现变种的有效性。
Bull Natl Res Cent. 2022;46(1):96. doi: 10.1186/s42269-022-00787-z. Epub 2022 Apr 8.
7
Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice.三价 NDV-HXP-S 疫苗可预防小鼠中亲缘关系较远的 SARS-CoV-2 关切变异株。
Microbiol Spectr. 2022 Jun 29;10(3):e0153822. doi: 10.1128/spectrum.01538-22. Epub 2022 Jun 6.
8
Recipients of COVID-19 vaccines face challenges of SARS-CoV-2 variants.接种 COVID-19 疫苗的人面临 SARS-CoV-2 变异体的挑战。
Int J Biol Sci. 2022 Jul 11;18(12):4642-4647. doi: 10.7150/ijbs.72424. eCollection 2022.
9
The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.新冠病毒-19（Sars-Cov-2）的英国变体不应造成疫苗问题。
J Biol Regul Homeost Agents. 2021 Jan-Feb;35(1):1-4. doi: 10.23812/21-3-E.
10
Nanotechnology-based strategies against SARS-CoV-2 variants.基于纳米技术对抗新冠病毒变异株的策略。
Nat Nanotechnol. 2022 Oct;17(10):1027-1037. doi: 10.1038/s41565-022-01174-5. Epub 2022 Aug 18.
引用本文的文献
1
Evaluation of COVID-19 Booster Vaccine Effectiveness.新型冠状病毒肺炎加强针疫苗有效性评估
Viruses. 2025 Jan 26;17(2):179. doi: 10.3390/v17020179.
本文引用的文献
1
Transplacental Transfer of Maternal Antibody against SARS-CoV-2 and Its Influencing Factors: A Review.母体抗SARS-CoV-2抗体的胎盘转运及其影响因素：综述
Vaccines (Basel). 2022 Jul 6;10(7):1083. doi: 10.3390/vaccines10071083.
2
The Dynamics of Changes in the Concentration of IgG against the S1 Subunit in Polish Healthcare Workers in the Period from 1 to 12 Months after Injection, Including Four COVID-19 Vaccines.波兰医护人员在接种包括四种新冠疫苗在内的疫苗后1至12个月内，针对S1亚基的IgG浓度变化动态。
Vaccines (Basel). 2022 Mar 24;10(4):506. doi: 10.3390/vaccines10040506.
3
The Landscape of COVID-19 Vaccination in Zimbabwe: A Narrative Review and Analysis of the Strengths, Weaknesses, Opportunities and Threats of the Programme.津巴布韦的新冠疫苗接种情况：对该计划的优势、劣势、机遇和威胁的叙述性综述与分析
Vaccines (Basel). 2022 Feb 9;10(2):262. doi: 10.3390/vaccines10020262.
4
Development of an Oral -Based Vaccine Platform against SARS-CoV-2.一种针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的口服疫苗平台的研发
Vaccines (Basel). 2022 Jan 1;10(1):67. doi: 10.3390/vaccines10010067.
5
Eosinophilic Granulomatosis with Polyangiitis Relapse after COVID-19 Vaccination: A Case Report.新型冠状病毒肺炎疫苗接种后嗜酸性肉芽肿性多血管炎复发：一例报告
Vaccines (Basel). 2021 Dec 23;10(1):13. doi: 10.3390/vaccines10010013.
Zotero 插件